Detection of insulitis by pancreatic scintigraphy with 99mTc-Labeled IL-2 and MRI in patients with LADA (Action LADA 10)

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 652-658

  Signore, Alberto ^a,b   Capriotti, Gabriela ^a   Chianelli, Marco ^b,c   Bonanno, Elena ^d   Galli, Filippo ^a   Catalano, Carlo ^e   Quintero, Ana M ^f   De Toma, Giorgio ^e   Manfrini, Silvia ^g   Pozzilli, Paolo ^g,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f University Campus Bio Medico ^*  (Colombia)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^h ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 TC 99M; ORAL ANTIDIABETIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CONTRAST MEDIUM; INSULIN ANTIBODY; INTERLEUKIN 2; TECHNETIUM COMPLEX; TECHNETIUM TC 99M INTERLEUKIN 2;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LATENT AUTOIMMUNE DIABETES IN ADULT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PANCREAS SCINTISCANNING; PANCREAS SURGERY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT DURATION; AGED; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC USE; IMMUNOLOGY; MIDDLE AGED; PANCREAS; PANCREATITIS; PATHOLOGY; SCINTISCANNING; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CONTRAST MEDIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN ANTIBODIES; INTERLEUKIN-2; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PANCREAS; PANCREATITIS; YOUNG ADULT;

EID: 84942785779     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0580     Document Type: Article

References (28)

1. Lo B, Swafford AD, Shafer-Weaver KA, et al. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. J Transl Med 2011;9:203.
2. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and longterm type 1 diabetes patients. J Exp Med 2012; 209:51-60.
3. Graham KL, Krishnamurthy B, Fynch S, et al. Intra-islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression. Eur J Immunol 2012;42:1717-1722.
4. Pozzilli P, Guglielmi C, Maggi D, Carlone A, Buzzetti R, Manfrini S. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes. Curr Pharm Des 2011;17:3224-3228.
5. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99mlabelled interleukin-2: A new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997;24:579-586.
6. Signore A, Parman A, Pozzilli P, Andreani D, Beverley PC. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: An early sign of type 1 diabetes. Lancet 1987;2:537-540.
7. Signore A, Chianelli M, Toscano A, et al. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nucl Med Commun 1992;13:713-722.
8. Signore A, Chianelli M, Ferretti E, et al. New approach for in vivo detection of insulitis in type I diabetes: Activated lymphocyte targeting with 123I-labelled interleukin 2. Eur J Endocrinol 1994;131:431-437.
9. Signore A, Chianelli M, Annovazzi A, et al. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur J Nucl Med 2000;27:18-24.
10. Signore A, Chianelli M, Annovazzi A, et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000;41:242-249.
11. Annovazzi A, Biancone L, Caviglia R, et al. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003;30:374-382.
12. Signore A, Bonanno E, De Toma G, et al. 99mTc-Interleukin-2 scintigraphy for imaging unstable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 2):S203.
13. Signore A, Annovazzi A, Barone R, et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: A validation study. J Nucl Med 2004;45:1647-1652.
14. Chianelli M, Parisella MG, Visalli N, et al.; IMDIAB study group. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab Res Rev 2008;24:115-122.
15. Karczmarczyk U, Garnuszek P, Maurin M, et al. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. Nucl Med Biol 2010;37:795-803.
16. D'Alessandria C, di Gialleonardo V, Chianelli M, et al. Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol 2010;12:539-546.
17. Hawa MI, Kolb H, Schloot N, et al.; Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908-913.
18. Emmrich J, Sparmann G, Hopt U, Lohr M, Liebe S. Typing of leukocytes in pancreatic tissue surrounding human pancreatic carcinoma. Ann N Y Acad Sci 1999;880:171-174.
19. Barone R, Procaccini E, Chianelli M, et al. Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes. Eur J Nucl Med 1998;25:503-508.
20. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLAmolecules in the pancreas in diabetic insulitis. N Engl J Med 1985;313:353-360.
21. Kaldany A, Hill T, Wentworth S, et al. Trapping of peripheral blood lymphocytes in the pancreas of patients with acute-onset insulin-dependent diabetes mellitus. Diabetes 1982;31:463-466.
22. Gallina DL, Pelletier D, Doherty P, et al. 111Indium-labelled lymphocytes do not image or label the pancreas of the BB/W rat. Diabetologia 1985;28:143-147.
23. Kolb H. Benign versus destructive insulitis. Diabetes Metab Rev 1997;13:139-146.
24. Signore A, Chianelli M, Ronga G, Pozzilli P, Beverley PC. In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes. Prog Clin Biol Res 1990;355:229-238.
25. Signore A, Picarelli A, Chianelli M, et al. Iinterleukin- 2 scintigraphy: A new approach to assess disease activity in autoimmunity. J Pediatr Endocrinol Metab. 1996;9(Suppl. 1):139-144.
26. Sweet IR, Cook DL, Lernmark A, et al. Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun 2004;314:976-983.
27. Di Gialleonardo V, Signore A, Glaudemans AW, Dierckx RA, De Vries EFN. N-(4-18Ffluorobenzoyl) interleukin-2 for PET of humanactivated T lymphocytes. J Nucl Med 2012;53: 679-686.
28. Di Gialleonardo V, Signore A, Willemsen AT, Sijbesma JW, Dierckx RA, de Vries EF. Pharmacokinetic modelling of N-(4- [(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur J Nucl Med Mol Imaging 2012;39:1551-1560.